233 related articles for article (PubMed ID: 8996351)
1. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
2. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
3. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
4. Bone metabolic markers in bone metastases.
Koizumi M; Yamada Y; Takiguchi T; Nomura E; Furukawa M; Kitahara T; Yamashita T; Maeda H; Takahashi S; Aiba K
J Cancer Res Clin Oncol; 1995; 121(9-10):542-8. PubMed ID: 7559734
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between specific prostatic antigen and findings with total body bone scintigraphy].
López M; Montes De Oca L; Bernardo N; Scorticati C; Suárez P; Bencardino F; De Lasa T; Sotero Falco E; Coimbra F; Scorticati C
Arch Esp Urol; 1996 Nov; 49(9):953-5. PubMed ID: 9133295
[TBL] [Abstract][Full Text] [Related]
6. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
8. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Oommen R; Geethanjali FS; Gopalakrishnan G; Chacko N; John S; Kanagasabapathy AS; Roul RK
Br J Radiol; 1994 May; 67(797):469-71. PubMed ID: 7514940
[TBL] [Abstract][Full Text] [Related]
9. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
[TBL] [Abstract][Full Text] [Related]
10. [Carcinoma of the prostate: correlation between local staging and systemic progression].
Rosi P; Marzi M; Mearini E; Bracarda S; Valli PP; Petroni PA; Porena M
Arch Ital Urol Androl; 1996 Dec; 68(5 Suppl):91-5. PubMed ID: 9162385
[TBL] [Abstract][Full Text] [Related]
11. PSA and bone scintigraphy.
Modoni S; Calò E; Nardella G; Ritrovato G; Frusciante V
Int J Biol Markers; 1997; 12(4):158-61. PubMed ID: 9582605
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
13. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Haukaas S; Roervik J; Halvorsen OJ; Foelling M
Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
[TBL] [Abstract][Full Text] [Related]
14. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
15. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
Koga H; Naito S; Koto S; Sakamoto N; Nakashima M; Yamasaki T; Noma H; Kumazawa J
Prostate; 1999 Apr; 39(1):1-7. PubMed ID: 10221259
[TBL] [Abstract][Full Text] [Related]
16. [Intraoperative scintigraphic visualization of a single rib metastasis from operated prostatic adenocarcinoma].
Sanjurjo S; Hamida W; Letesson G; Hustinx R; Gillet P; Andrianne R
Prog Urol; 2008 Jun; 18(6):402-5. PubMed ID: 18558331
[TBL] [Abstract][Full Text] [Related]
17. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen level and risk of bone metastasis in Sudanese patients with prostate cancer.
Khalid KE; Brair AI; Elhaj AM; Ali KE
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1041-3. PubMed ID: 21912047
[No Abstract] [Full Text] [Related]
19. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
20. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
